Q1 2026 Orchid Pharma Ltd Earnings Call Transcript
Key Points
- Orchid Pharma Ltd (BOM:524372) maintained its gross margins at around 42% despite a challenging market environment.
- The company acquired global rights to enmetazobactam and the trademark Exblifep from Allecra, enhancing its strategic position.
- Orchid Pharma Ltd (BOM:524372) is now the only Indian pharmaceutical company with an internationally approved new chemical entity.
- The acquisition of enmetazobactam is expected to bring significant economic benefits, including direct royalties from ADVANZ in Europe.
- The 7ACA project in Jammu is progressing as planned, which will strengthen API capabilities and reduce import dependencies.
- Sales for Q1 FY26 declined by 29% compared to the same period last year, due to a global slowdown in the antibiotics market.
- The antibiotics industry is experiencing a sharp contraction, with export volumes and prices falling significantly.
- Persistent volume and price pressures in antibiotics could negatively impact near-term revenues.
- The acquisition of enmetazobactam from Allecra involves risks due to limited due diligence in insolvency acquisitions.
- The US market remains challenging for enmetazobactam, with no immediate entry planned.
Ladies and gentlemen, good day and welcome to the Q1 FY26 earnings conference call of Orchid Pharma Limited, hosted by Systematix Institutional Equities. (Operator Instructions)
Please note that this conference is been recorded. I now have the conference over to Mr. Vishal Manchanda from Systematix Institutional Equities. Thank you, and over to you, sir.
()-
Thank you, Muskan, and good evening everyone. On behalf of Systematix Institutional Equities, I welcome you to the Q1 FY26 earnings call of Orchid Pharma. We thank the Orchid management for giving us an opportunity to host the call today.
We have with us the senior management of the company represented by Mr. Manish Dhanuka, Managing Director; Mr. Mridul Dhanuka, Whole-Time Director; and Mr. Sunil Kumar Gupta, Chief Financial Officer. I'll now hand over the call to the company management for their opening remarks. Over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
